by Elec23 | Oct 23, 2025 | News&events
We are proud to be part of Clover Biopharmaceuticals’ important achievement in advancing innovative respiratory combination vaccines. VisMederi contributed to the RSV+hMPV±PIV3 Combination Vaccines Phase I study by performing serological analyses, supporting the...
by Elec23 | Oct 22, 2025 | News&events
VisMederi continues to strengthen its engagement in metapneumovirus control and vaccine research, confirming its active role in the international scientific community. At the 10th ESWI Influenza Conference, held in Valencia from 20 to 23 October 2025, Maria Giovanna...
by Elec23 | Oct 17, 2025 | News&events
Our team wrapped up an inspiring and productive week at the World Vaccine Congress Europe 2025 in Amsterdam — the leading European event dedicated to vaccines, held from October 13 to 16 at the RAI Congress Center. It was an invaluable opportunity to engage with some...
by Elec23 | Oct 16, 2025 | News&events
During the event, Luisa presented the key role that VisMederi will play in the upcoming Phase 2b clinical study. The meeting provided a valuable opportunity for in-depth discussions and fruitful exchanges on study details with investigators and partners. We would like...
by Elec23 | Oct 16, 2025 | News&events
VisMederi’s Cell Mediated Immunity (CMI) Team members, Ilaria Razzano and Ilaria Ferrigno, traveled to Sofia to deliver a training session at Hera Medical Center. The focus of the training was on PBMC (Peripheral Blood Mononuclear Cells) isolation from clinical...
